Systemic Anti-Cancer Treatment Protocol

Sandostatin LAR (Octreotide)

PROTOCOL REF: MPHASANOST
(Version No. 1.0)

Approved for use in:

- Treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours e.g. carcinoid tumours with features of the carcinoid syndrome
- Treatment of patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded

Dosage:

Recommended starting dose:

Drug	Dosage	Route	Frequency
Sandostatin LAR	20mg	IM	Every 28 days

If symptoms only partially controlled after 3 months:

Drug	Dosage	Route	Frequency
Sandostatin LAR	30mg	IM	Every 28 days

If symptoms well controlled after 3 months (possibly reduce):

Drug	Dosage	Route	Frequency
Sandostatin LAR	10mg	IM	Every 28 days

Supportive Treatments:

N/A

Extravasation risk:

N/A

Administration:

Sandostatin LAR may only be administered by deep intramuscular injection. The site of repeat intramuscular injections should be alternated between the left and right gluteal muscle.

The injection kit must be allowed to reach room temperature. Remove kit from fridge at least 30 minutes before reconstitution (maximum 24 hours). Please refer to information leaflet inside kit for reconstitution and administration information.

Main toxicities

Skin/ Admin Site	Injection site reactions, pruritus, rash, alopecia
Immune System	Allergic reactions (including angioedema, anaphylaxis, hypersensitivity)
Nervous System	Headache, dizziness
Gastrointestinal	Diarrhoea, abdominal pain, nausea, vomiting, flatulence, abdominal bloating, steatorrhoea, dyspepsia, constipation
Endocrine disorders	Hypothyroidism, thyroid dysfunction (decreased TSH, decreased total T4, decreased free T4)
Cardiac	Bradycardia, tachycardia
Respiratory	Dyspnoea
Metabolism/ Nutrition disorders	Hyperglycaemia, hypoglycaemia, impaired glucose tolerance, anorexia, dehydration
Hepatobiliary	Cholelithiasis, cholecystitis, hyperbilirubinaemia, elevated transaminase levels

Investigations and Treatment Plan:

	Pre	C1	C2	C3	C4	Ongoing
Medical Assessment	X		X	X	X	Every cycle for first 3 cycles then every 3 months (unless clinically indicated)
Nursing Assessment		X	X	X	X	Every cycle
U&E & LFTs	X		X	X	X	Every cycle
FBC	X		X	X	X	Every cycle
TFTs	X				X	Every 12 weeks (unless clinically indicated)
Blood Glucose	X		X	X	X	Every cycle
CT scan	X				X	Every 3 months (unless clinically indicated)
Informed Consent	X					
PS recorded	X	X	X	X	X	Every Cycle
Toxicities documented	X	X	X	X	X	Every Cycle
Weight recorded	X	X	X	X	X	Every cycle

References:

Sandostatin LAR, Summary of Product Characteristics. Novartis Pharmaceuticals UK Ltd. Available from https://www.medicines.org.uk/emc/product/1038/smpc Last updated 03/03/2016.